EHA25 | Venetoclax addition improves survival in chemotherapy-ineliglible patients with AML

Courtney DiNardo discusses the phase 3 VIALE-A study supporting the addition of venetoclax to azacitidine as a new standard of care option for the first-line treatment of acute myeloid leukaemia patients who are ineligible for intensive chemotherapy (4:31).